Status:
COMPLETED
Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology
Lead Sponsor:
Eisai Inc.
Conditions:
Thyroid Cancer
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the safety and efficacy of oral lenvatinib in participants with medullary thyroid cancer (MTC) or radioiodine (131 I)-refractory/resistant differentiated thyr...
Detailed Description
This study contained 3 Phases: the Pretreatment Phase, the Treatment Phase, and the Extension Phase. The Pretreatment Phase lasted no longer than 28 days. Informed consent was obtained and protocol el...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Histologically or cytologically confirmed diagnosis of medullary thyroid cancer (MTC) or differentiated thyroid cancer (DTC).
- Measurable disease meeting the following criterion:
- At least one lesion (greater than or equal to 1.5 cm in longest diameter for non-lymph nodes and greater than or equal to 2.0 cm in longest diameter for lymph nodes) which is serially and accurately measurable according to modified response evaluation criteria in solid tumours (RECIST) using either computed tomography (CT) or magnetic resonance imaging (MRI).
- Lesions that have had electron beam radiotherapy must show evidence of progressive disease based on modified RECIST to be deemed a target lesion.
- Evidence of disease progression by RECIST using site assessment of CT/MRI scans within 12 months (+1 month to allow for variances in patient scanning intervals) prior to study entry.
- DTC must be 131-I refractory/resistant: never demonstrated 131-I uptake, progression despite 131-I uptake, or cumulative dose of 131-I of greater than 600 millicurie (mCi) (last dose given at least 6 months prior to study entry).
- Well controlled blood pressure prior to study entry.
- Exclusion criteria:
- Anaplastic thyroid carcinoma, thyroid lymphoma, mesenchymal tumors of the thyroid, metastases to the thyroid.
- Brain or leptomeningeal metastases.
- Significant cardiovascular impairment (history of congestive heart failure, New York Heart Association \[NYHA\] Class II, unstable angina or myocardial infarction within 6 months of study start, or serious cardiac arrhythmia).
- Marked baseline prolongation of QT/corrected QT (QTc) interval.
- Proteinuria greater than 1+ or greater than 30 mg in dipstick testing.
- Active hemoptysis (bright red blood of at least one-half teaspoon) in the 28 days prior to study entry.
Exclusion
Key Trial Info
Start Date :
November 6 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 29 2019
Estimated Enrollment :
117 Patients enrolled
Trial Details
Trial ID
NCT00784303
Start Date
November 6 2008
End Date
March 29 2019
Last Update
April 22 2020
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Little Rock, Arkansas, United States
2
Los Angeles, California, United States
3
Los Gatos, California, United States
4
Mission Viejo, California, United States